Early Access — free while we kick the tires
EdgarHawk

M33 Growth I L.P.

Director

Director 10% Owner
3 filings analyzed · 1 company · Latest 2025-09-05

Companies

Company Buys Sells Direction
Oncology Institute, Inc. TOI 0 6 Net selling

Activity

September 2025
high
Sell
6,700,000 shares
$20,703,000
Significance 7/10

M33 Growth I L.P. (Director) sold 6,700,000 shares (6.70M) at $3.09 on 2025-09-04 for $20,703,000.00, reducing stake by 91.9%

M33 Growth I L.P. executed two separate sales totaling 6,700,000 shares (6.70M shares) at $3.09 on 2025-09-04, generating $20,703,000.00 and leaving only 590,892 shares (590.9K shares) in post-transaction holdings—a 91.9% reduction from the 7,290,892 shares held before. The sales occurred at $3.09, below the current price of $3.30 yet within the 52-week range of $0.13–$4.28. The underlying company has posted quarterly revenue of $119,802,000.00 ($119.8M) with a net loss of -$17,009,000.00 (-$17.0M) and was unprofitable over its most recent full fiscal year, though annual revenue growth reached +21.3%. At the same ticker (TOI), this insider's prior 4 sales (completed in June and May 2025) generated 90-day returns of +5.9%, +5.9%, +48.9%, and +48.9%, meaning none of those prior sales were well-timed by the 90-day measure. The near-complete departure from this position, combined with the company's ongoing net losses despite revenue growth, represents a material shift in insider holding conviction.

June 2025
medium
Sell
750,000 shares
$2,287,500
Significance 6/10

Director M33 Growth I L.P. sold 750,000 shares (37.1% reduction) at $3.05 for $2,287,500 on 2025-06-05

M33 Growth I L.P. executed 2 separate sales totaling 750,000 shares at $3.05 on 2025-06-05, reducing holdings from 2,022,724 to 1,272,724 shares. This represents a -37.1% reduction in position size. The transaction occurred while the stock was 21.4% below its 52-week high of $3.31, and current price is now $2.60 — a 14.8% markdown from the execution price. The company is unprofitable (latest net income: -$19,585,000) with quarterly revenue of $104,406,000 and annual growth of 21.3%, creating a mixed signal where fundamental losses offset operational expansion. The director's prior trades at TOI occurred on 2025-05-20 (2 sells) with 90-day outcomes still immeasurable, so this filing provides no baseline for evaluating timing consistency at this ticker.

May 2025
high
Sell
2,000,000 shares
$5,425,800
Significance 7/10

M33 Growth I L.P. director sells 2,000,000 shares (59.7% of holdings) at $2.71 amid negative earnings

M33 Growth I L.P. executed 2 separate sales totaling 2,000,000 shares for $5,425,800.00 on 2025-05-20, reducing holdings by 59.7% from 3,349,048 shares to 1,349,048 shares. The sales occurred at $2.71 per share, roughly 9.4% below the current price of $2.99. While the company shows revenue growth of 21.3% year-over-year and has appreciated 236.0% over 90 days, it remains unprofitable with net income of $-19,585,000.00 on quarterly revenue of $104,406,000.00, creating tension between growth momentum and fundamental weakness. A substantial reduction in a major stakeholder's position during a period of unprofitability warrants attention to whether this reflects a strategic shift in the director's exposure to the company.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access